SEC Form 4 · accession 0001780854-26-000008
Adaptive Biotechnologies Corp · ADPT
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Sharon Benzeno
Officer — Chief Commercial Ofc Imm Med
Period of report
Jun 26, 2026
Accepted (ET)
Jun 30, 2026 · 7:25 pm EDT
Rule 10b5-1 plan
yes — trade under a plan
Issuer CIK
0001478320
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Jun 26, 2026 | M | 11,034 | $12.14 | A | 283,785 | D | |
| Common StockF2 | Jun 26, 2026 | S | 11,034 | $21.00 | D | 272,751 | D | |
| Common Stock | Jun 29, 2026 | M | 1,837 | $12.14 | A | 274,588 | D | |
| Common Stock | Jun 29, 2026 | M | 24,944 | $8.46 | A | 299,532 | D | |
| Common Stock | Jun 29, 2026 | M | 24,944 | $3.99 | A | 324,476 | D | |
| Common Stock | Jun 29, 2026 | M | 51,570 | $8.12 | A | 376,046 | D | |
| Common StockF3 | Jun 29, 2026 | S | 154,768 | $21.14 | D | 221,278 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F4 | $12.14 | Jun 26, 2026 | M | 11,034 | D | — | Mar 4, 2032 | Common Stock | 11,034 | 1,837 | D |
| Stock Option (right to buy)F4 | $12.14 | Jun 29, 2026 | M | 1,837 | D | — | Mar 4, 2032 | Common Stock | 1,837 | 0 | D |
| Stock Option (right to buy)F5 | $8.46 | Jun 29, 2026 | M | 24,944 | D | — | Mar 6, 2033 | Common Stock | 24,944 | 37,416 | D |
| Stock Option (right to buy)F6 | $3.99 | Jun 29, 2026 | M | 24,944 | D | — | Mar 4, 2034 | Common Stock | 24,944 | 87,303 | D |
| Stock Option (right to buy)F7 | $8.12 | Jun 29, 2026 | M | 51,570 | D | — | Mar 4, 2035 | Common Stock | 51,570 | 113,457 | D |
Explanation of responses
- F1The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 12, 2025.
- F2The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $21.00 to $21.01, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.
- F3The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $21.00 to $21.38, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.
- F4The option was fully vested and exercisable.
- F5The options vested with respect to 1/4 of such shares on March 4, 2024, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested.
- F6The options vested with respect to 1/4 of such shares on March 4, 2025, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested.
- F7The options vested with respect to 1/4 of such shares on March 4, 2026, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested.